Company profile
Cytosorbents Corporation
NASDAQ: CTSO · Healthcare · Medical - Devices
#475 of 1,418 Healthcare companies by revenue47th-percentile growth
EA Score
55CFH 48DQ 63GM 55SS 65
v0.1 · 65/100 weight · provisional
↑ disclosure history, 3-yr revenue growth · ↓ return on equity, growth stability
Methodology →Revenue TTM
$37.2M
Rev growth YoY (TTM)
+5.3%
Net income (FY)
-$8.2M
Employees
129
as of 2026-08-21
Market cap
$19.6M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$37.1M$37.1M2025
Net income-$8.2M-$8.2M2025
Operating income-$14.7M-$14.7M2025
Total assets$44.2M$44.2M2025
Liabilities$38.3M$38.3M2025
Equity$5.9M$5.9M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cytosorbents Corporation’s revenue?
Cytosorbents Corporation booked $37.1M in FY2025 revenue, growing 4.1% year over year — about the middle of the pack among Healthcare companies we track, at a -22.1% net margin.
Peers · Healthcare
Palvella Therapeutics, Inc.54DUtah Medical Products, Inc.80B+Retractable Technologies, Inc.57CClearPoint Neuro, Inc.62CSunshine Biopharma, Inc.50DC4 Therapeutics, Inc.49DNeighbors
Mercer →Key facts
CEOPhillip Chan
SectorHealthcare
IndustryMedical - Devices
HeadquartersPrinceton, NJ
ExchangeNASDAQ: CTSO
Employees129
IPO date2006-08-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.